Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cLSC for Limbal Stem Cell Deficiency
NCT03957954Phase 1Active, not recruiting
- Sponsor
- University of California, Los Angeles
- Start
- Sep 2020
- Primary completion
- Feb 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ex vivo reconstructed autologous human corneal epithelium containing stem cells in limbal stem cell deficiency (LSCD) (2 arms), sponsored by University of California, Los Angeles. Primary endpoints: Safety of cLSC Transplant pertaining to Infection and/or Corneal Perforation at 12 months, Feasibility of cLSC Transplant pertaining to Manufacturing meeting Release Criteria at 12 months and 1 more. Started Sep 2020; status: active, not recruiting.
02
Drugs
ex vivo reconstructed autologous human corneal epithelium containing stem cells
03
Conditions
limbal stem cell deficiency (LSCD)
Beyond the preview
Go deeper on NCT03957954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03957954.